Understanding Gastroparesis: A Comprehensive Overview
Gastroparesis is a chronic digestive condition characterized by delayed gastric emptying—the stomach’s inability to properly move food into the small intestine. Despite normal mechanical function (no blockages or obstructions), patients experience significant symptoms that can severely impact their quality of life.
Common Symptoms Include:
- Severe nausea and vomiting
- Early satiety (feeling full too quickly)
- Abdominal pain and bloating
- Loss of appetite and weight loss
- Difficulty maintaining proper nutrition
- Postprandial fullness and discomfort
The condition affects patients with both idiopathic gastroparesis (no identifiable cause) and diabetic gastroparesis(related to diabetes complications).
Medical Marijuana and Cannabinoids: An Emerging Treatment Option
As traditional gastroparesis treatments fall short for many patients, medical professionals are increasingly exploring medical marijuana and cannabinoids as potential therapeutic alternatives. Recent research has shed new light on how these compounds may help manage gastroparesis symptoms.
How Cannabinoids Work
Cannabinoids exert their therapeutic effects through multiple mechanisms:
- Anti-emetic properties: Cannabinoids mediate nausea relief via CB1 receptors in the brainstem
- Appetite stimulation: Known as orexigenic effects, helping patients maintain nutrition—medical marijuana’s role in appetite stimulation is particularly beneficial for gastroparesis patients
- Pain relief: Analgesic properties addressing abdominal discomfort
- Anti-inflammatory effects: Particularly through CB2 receptor activation
- Sensory modulation: Reducing visceral and somatic sensation disturbances
Groundbreaking Research: CBD and Gastroparesis
Mayo Clinic’s Landmark Study
One of the most significant recent advances comes from Mayo Clinic, where researchers conducted a rigorous, double-blind, placebo-controlled clinical trial examining the efficacy of pharmaceutical-grade cannabidiol (CBD) in gastroparesis patients.
Study Details:
- Duration: 4 weeks of treatment
- Participants: 44 patients (32 with idiopathic gastroparesis, 12 with diabetes-related gastroparesis)
- Treatment: Twice-daily oral CBD, escalated up to 20 mg/kg/day
- Study Period: September 2020 to March 2023
Key Findings:
The results were remarkable. CBD treatment demonstrated statistically significant improvements across multiple measures:
- Reduced Gastroparesis Cardinal Symptom Index (GCSI) score (P = .008)
- Decreased inability to finish a normal-sized meal (P = .029)
- Reduced number of vomiting episodes per 24 hours (P = .006)
- Lower overall symptom severity (P = .034)
- Improved tolerance of liquid nutrient intake
- Greater volume to comfortable fullness and maximum tolerated volume
Importantly, these benefits occurred despite some slowing of gastric emptying, suggesting that CBD’s symptom relief works through sensory and anti-inflammatory mechanisms rather than by accelerating stomach function.
Learn more: Read the full Mayo Clinic study on CBD and Gastroparesis published in Clinical Gastroenterology and Hepatology.
Adverse Event Profile
CBD was well-tolerated overall. The most commonly reported side effects were:
- Diarrhea (14 patients)
- Fatigue (8 patients)
- Headache (8 patients)
- Nausea (7 patients)
These adverse events were generally mild and comparable to placebo in many cases, with 95% of participants completing the full 4-week study.
Source: Mayo Clinic Research Summary
Current Cannabis Use in Gastroparesis Patients
Prevalence Studies
Recent epidemiological research has examined how many gastroparesis patients currently use cannabis and their reported benefits.
NIH Gastroparesis Clinical Research Consortium Study:
A landmark study published in Digestive Diseases and Science analyzed data from the National Institutes of Diabetes and Digestive and Kidney Diseases-sponsored Gastroparesis Clinical Research Consortium:
- Prevalence: 59 of 506 (11.7%) patients with gastroparesis symptoms reported current marijuana use
- Usage patterns: Similar prevalence among both delayed gastric emptying and normal gastric emptying patients
- Disease type: Similar rates in idiopathic and diabetic gastroparesis patients
- Patient perception: Remarkably, 81% of cannabis users reported perceived benefit from marijuana use for symptom management
The study notes that while theoretical benefits are promising—particularly the anti-emetic, orexigenic, and analgesic effects—clinical evidence remains limited and requires careful evaluation.
Read the full study: Marijuana Use in Patients with Symptoms of Gastroparesis from the NIH Gastroparesis Consortium.
Large Population Study (2023)
A 2023 analysis examining 50,170 hospitalized gastroparesis patients found:
- Cannabis use prevalence: 4.2% of gastroparesis patients
- Association with demographics: Users were younger, more likely male, and of African American or Asian descent
- Symptom improvement: Cannabis use was associated with lower odds of vomiting
- Healthcare utilization: Important consideration for overall treatment strategy
Reference: Cannabis Use in Patients with Gastroparesis published in Cannabis and Cannabinoid Research.
Important Considerations: Cannabis Use and Gastroparesis
Potential Concerns and Cautions
While patient-reported benefits are encouraging, medical professionals emphasize the importance of careful risk-benefit analysis:
THC and Gastric Emptying:
- Research indicates that THC may actually slow gastric emptying in some cases
- Older literature suggested THC doesn’t affect gastric motility, but more recent studies suggest cannabinoid agonists can slow GI motility and inhibit gastric acid secretion
- Dronabinol (synthetic THC) has been documented to delay gastric emptying of solid food
Healthcare Utilization Patterns: Recent research from Washington University showed that among matched gastroparesis patients:
- Cannabis users had 1.73 times higher emergency department visit rates
- 1.44 times higher hospitalization rates
- These increases suggest the need for careful monitoring and patient selection
Key Takeaway: While patients report symptom relief, particularly for nausea and pain, careful medical evaluation is essential to determine whether cannabis use is appropriate for individual patients and to monitor for potential complications.
Read the analysis: The Impact of Cannabis Use in Gastroparesis from the American Journal of Gastroenterology.
Comparing Treatment Options: Synthetic Cannabinoids vs. Medical Marijuana
Dronabinol (Marinol)
Dronabinol is a synthetic form of THC that is FDA-approved for chemotherapy-induced nausea and vomiting. For gastroparesis specifically, gastroenterology research has documented potential benefits for medical marijuana for nauseamanagement, though with important limitations:
- Some patients report symptomatic benefit for pain and nausea
- However, THC’s gastric motility effects present complications
- Central nervous system effects and psychoactive properties may limit tolerance
Pharmaceutical-Grade CBD
CBD offers several theoretical advantages:
- Reduced psychoactive effects compared to THC
- Anti-inflammatory mechanisms via CB2 receptors
- Sensory modulation without psychic impairment
- Demonstrated symptom relief in randomized controlled trials
Medical Cannabis
Natural cannabis products:
- Contain variable THC/CBD ratios
- Provide patient-perceived benefit (81% reported improvement)
- Require careful strain selection and dosing
- Present variable quality and consistency issues
The Role of Genetic Factors in Treatment Response
Emerging research has identified genetic variations that may predict CBD response in gastroparesis patients. The FAAH rs324420 genotype significantly impacted nutrient drink ingestion in the Mayo Clinic trial, suggesting that future treatment may become more personalized based on genetic testing.
This represents an exciting frontier in precision medicine for gastroparesis management, though more research is needed to fully understand these associations.
Meeting with Miami’s Top Marijuana Doctor: Dr. Fernando Fandiño-Sende
Why Choose an Experienced Cannabis Medicine Specialist?
Dr. Fernando Fandiño-Sende brings unique qualifications to cannabis medicine consultation:
Credentials:
- Double Board-Certified in Cardiology
- Board-Certified in Internal Medicine
- Extensive training in cardiovascular and systemic health
Why This Matters for Gastroparesis Patients:
Gastroparesis patients often have:
- Underlying cardiovascular concerns (particularly in diabetic gastroparesis)
- Complex medication interactions
- Comorbid conditions requiring comprehensive medical evaluation
- Need for careful monitoring of systemic effects
A physician with dual board certification in cardiology and internal medicine brings critical expertise in understanding how medical marijuana might interact with your complete health profile.
Comprehensive Medical Cannabis Consultation
Dr. Fandiño-Sende’s approach includes:
- Thorough Medical History: Understanding your specific gastroparesis presentation, symptom severity, and response to prior treatments
- Cardiovascular Assessment: Ensuring cannabis use is safe given your cardiovascular status (particularly important for diabetes patients)
- Medication Review: Identifying potential interactions with your current treatments
- Treatment Plan Development: Creating a personalized approach with appropriate products, dosing, and monitoring
- Ongoing Management: Regular follow-up to ensure effectiveness and safety
LifeCannMD: Miami’s Comprehensive Cannabis Medicine Center
LifeCannMD provides evidence-based medical marijuana consultations in Miami, combining:
- Board-certified expertise
- Current research understanding
- Individualized treatment planning
- Compassionate patient care
- Access to pharmaceutical-grade cannabis products
Current Research Landscape and Future Directions
What the Evidence Currently Shows
The scientific consensus is evolving:
- Positive: Patient symptom relief is demonstrable and reported by up to 81% of users
- Promising: Pharmaceutical-grade CBD shows measurable improvements in gastroenterology metrics
- Cautious: Healthcare utilization patterns suggest complex clinical effects requiring monitoring
- Emerging: Genetic factors may predict optimal treatment response
Upcoming Research
Major clinical centers are pursuing:
- Longer-term efficacy studies (beyond 4 weeks)
- Larger, more diverse patient populations
- Combination therapy research (CBD with metoclopramide)
- Better understanding of THC vs. CBD mechanisms
- Identification of optimal candidate profiles
Source: Cannabinoids and the Gastrointestinal Tract – Comprehensive review of cannabinoid mechanisms in GI disease.
Is Medical Marijuana Right for Your Gastroparesis?
Considerations for Treatment Selection
Medical marijuana may be worth exploring if you:
- Experience inadequate symptom relief from conventional treatments
- Have significant nausea, vomiting, or abdominal pain—learn about pain management with medical marijuana
- Struggle with appetite and nutritional intake
- Have tolerated previous cannabis use without adverse effects
- Are willing to commit to medical monitoring
Medical marijuana may NOT be appropriate if you:
- Have untreated cardiovascular disease
- Are pregnant or breastfeeding
- Have a personal or family history of cannabis use disorder
- Take medications with significant cannabinoid interactions
- Have psychotic disorders or predisposition to psychosis
Getting Started: Next Steps
1. Consultation with a Cannabis Medicine Specialist
Schedule an appointment with Dr. Fernando Fandiño-Sende, our board-certified cannabis doctor in Miami, at LifeCannMD. Your consultation will include:
- Complete medical history and assessment
- Review of prior treatments and current medications
- Cardiovascular and systemic health evaluation
- Discussion of potential benefits and risks
- Personalized recommendations if appropriate
2. Medical Marijuana Card in Florida
If recommended, you’ll need a Florida medical marijuana card. The process includes:
- Registered physician recommendation from a Florida cannabis doctor
- Medical marijuana card application with the state
- Access to licensed dispensaries throughout Florida
3. Product Selection and Dosing
Your physician will recommend:
- Appropriate cannabinoid profile (CBD-dominant, THC-containing, or hybrid)
- Dosing schedule and route of administration
- Specific products from quality dispensaries
- Monitoring parameters
4. Ongoing Monitoring
Regular follow-up appointments to:
- Assess symptom improvement
- Monitor for adverse effects
- Evaluate healthcare utilization patterns
- Adjust treatment as needed
- Ensure continued safety
Frequently Asked Questions
Is Medical Marijuana Legal in Florida?
Yes. Florida has a medical marijuana program allowing patients with qualifying conditions for medical marijuana(including gastroparesis) to use cannabis under physician supervision. Learn more about how to get medical marijuana in Florida.
How Quickly Will I See Benefits?
Patient experiences vary:
- Some report symptom relief within days to weeks
- Research studies show measurable improvement over 4 weeks
- Individual response depends on underlying disease severity, product selection, and genetic factors
Will Medical Marijuana Replace My Current Medications?
Not necessarily. Many patients benefit from combined approaches:
- Medical marijuana + metoclopramide
- Medical marijuana + dietary modifications
- Medical marijuana + other symptom management strategies
Always consult with your physician before discontinuing any medications.
What Products Should I Use?
This depends on individual factors:
- CBD-dominant products: Research-backed for symptom relief, minimal psychoactive effects
- Low-THC products: Balance of symptom relief with reduced psychoactive effects
- High-THC products: May provide more significant pain and nausea relief but risk gastric motility effects
- Edibles vs. inhalation: Different onset times and duration of action—explore our guide on methods of delivery for medical marijuana
Your physician will provide specific recommendations based on your needs.
Are There Drug Interactions?
Potentially yes. Cannabis can interact with:
- Cardiovascular medications
- Diabetic medications
- Anticoagulants
- CNS medications
- Other medications metabolized by CYP3A4
A comprehensive medication review with your cannabis medicine specialist is essential.
Conclusion: A New Hope for Gastroparesis Patients
Gastroparesis remains a challenging condition with limited FDA-approved treatment options. However, emerging research into medical marijuana and cannabinoids—particularly pharmaceutical-grade CBD—offers new hope for patients struggling with traditional therapies.
Key takeaways:
- Research is promising: Mayo Clinic and other major institutions show measurable symptom improvement with CBD
- Patient reports are encouraging: 81% of current cannabis users report perceived benefit
- Individualization is critical: Response varies based on disease type, cannabinoid profile, and genetic factors
- Medical supervision matters: Working with a board-certified physician ensures safe, appropriate use
Schedule Your Consultation Today
If you’re struggling with gastroparesis and interested in exploring medical marijuana as a treatment option, Dr. Fernando Fandiño-Sende at LifeCannMD in Miami is ready to help.
With dual board certification in cardiology and internal medicine, Dr. Fandiño-Sende brings comprehensive medical expertise to cannabis medicine consultation—ensuring your treatment is safe, effective, and tailored to your complete health picture.
LifeCannMD: Miami’s Premier Medical Marijuana Doctor
- Location: Miami, Florida
- Specialist: Dr. Fernando Fandiño-Sende, MD
- Credentials: Double Board-Certified Cardiologist & Internal Medicine Specialist
- Focus: Evidence-based medical cannabis consultation for chronic digestive conditions
Research References and Scholarly Articles
Primary Research Studies
- Zheng T, BouSaba J, Taylor A, et al. “A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.” Clinical Gastroenterology and Hepatology. 2023 Dec;21(13):3405-3414.
- Parkman HP, Sharkey EP, Nguyen LA, et al. “Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit.” Digestive Diseases and Science. 2020 Aug;65(8):2311-2320.
- Kilani Y, Gonzalez Mosquera DA, Puelo PC, et al. “The Impact of Cannabis Use in Gastroparesis: A Propensity-Matched Analysis of 41,374 Gastroparesis Patients.” American Journal of Gastroenterology. 2026 Jan;121(1):248-257.
- Saleem S, Tarar ZI, Aziz M, et al. “Cannabis Use in Patients with Gastroparesis.” Cannabis and Cannabinoid Research. 2023 Dec;8(6):1100-1105.
Review Articles and Expert Analysis
- Maselli DB, Camilleri M. “Pharmacology, clinical effects, and therapeutic potential of cannabinoids for gastrointestinal and liver diseases.” Neurogastroenterology & Motility. 2023.
- American College of Gastroenterology Editorial. “Cannabidiol: A Potential Therapeutic Option for Idiopathic and Diabetic Gastroparesis.”
Mayo Clinic Resources
- Mayo Clinic Digestive Diseases Division. “Examining the Efficacy and Safety of CBD in Patients with Idiopathic and Diabetic Gastroparesis.”
Case Reports and Clinical Observations
- Marijuana-Induced Gastroparesis and Aspiration Risk.Case Report in Anesthesiology. 2021.
